{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:09:51Z","timestamp":1791896991808,"version":"4.3.4"},"reference-count":39,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"VQR improvement assigned to the Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties of the University of Palermo"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The current carbapenem-resistant gram-negative bacteria (CR-GN) treatment guidelines lack strong evidence about cefiderocol (CFD) efficacy against CR-GN, especially CRAB. The study\u2019s purpose is to evaluate the effectiveness of CFD in a real-life setting. We made a single-center retrospective study of 41 patients who received CFD in our hospital for several CR-GN infections. Bloodstream infections (BSI) affected 43.9% (18\/41) of patients, while CRAB affected 75.6% (31\/41) of isolated CR-GN patients. Thirty-days (30-D) all-causes mortality affected 36.6% (15\/41) of patients, while end-of-treatment (EOT) clinical cure affected 56.1% (23\/41). Finally, microbiological eradication at EOT affected 56.1% (23\/41) of patients. Univariate and multivariate analysis showed that septic shock is an independent factor associated with mortality. Subgroup analyses showed no difference in CFD effectiveness between monotherapy and combination therapy.<\/jats:p>","DOI":"10.3390\/antibiotics12040746","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T04:33:26Z","timestamp":1681360406000},"page":"746","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4986-0883","authenticated-orcid":false,"given":"Gabriele","family":"Palermo","sequence":"first","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties \u201cG D\u2019Alessandro\u201d, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-070X","authenticated-orcid":false,"given":"Alice Annalisa","family":"Medaglia","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight against AIDS, AOU Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"},{"name":"Antimicrobial Stewardship Team, AOU Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pipit\u00f2","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties \u201cG D\u2019Alessandro\u201d, University of Palermo, 90127 Palermo, Italy"},{"name":"Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight against AIDS, AOU Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Rubino","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight against AIDS, AOU Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"},{"name":"Antimicrobial Stewardship Team, AOU Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Costantini","sequence":"additional","affiliation":[{"name":"UOC Farmacia, AOU Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Accomando","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties \u201cG D\u2019Alessandro\u201d, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7874-6289","authenticated-orcid":false,"given":"Giovanni Maurizio","family":"Giammanco","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties \u201cG D\u2019Alessandro\u201d, University of Palermo, 90127 Palermo, Italy"},{"name":"Microbiology and Virology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties \u201cG D\u2019Alessandro\u201d, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-1796","authenticated-orcid":false,"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties \u201cG D\u2019Alessandro\u201d, University of Palermo, 90127 Palermo, Italy"},{"name":"Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight against AIDS, AOU Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"},{"name":"Antimicrobial Stewardship Team, AOU Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/eri.12.162","article-title":"Treatment of carbapenem-resistant Klebsiella pneumoniae: The state of the art","volume":"11","author":"Petrosillo","year":"2013","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_2","unstructured":"(2022, September 08). EMA Raccomanda L\u2019approvazione di Zavicefta per i Pazienti con Limitate Opzioni di Trattamento, Available online: https:\/\/www.aifa.gov.it\/-\/ema-raccomanda-l-approvazione-di-zavicefta-per-i-pazienti-con-limitate-opzioni-di-trattamento."},{"key":"ref_3","unstructured":"(2022, September 08). Comitato per i Medicinali per Uso Umano (CHMP) dell\u2019EMA: Highlights del Meeting di Febbraio, Available online: https:\/\/www.aifa.gov.it\/-\/comitato-per-i-medicinali-per-uso-umano-chmp-dell-ema-highlights-del-meeting-di-febbra-4."},{"key":"ref_4","unstructured":"(2022, September 08). EMA Raccomanda un Nuovo Medicinale per una Serie di Infezioni, Available online: https:\/\/www.aifa.gov.it\/-\/ema-raccomanda-un-nuovo-medicinale-per-una-serie-di-infezioni."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1060028020929988","article-title":"Cefiderocol: A Siderophore Cephalosporin","volume":"54","author":"Rizk","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Volpicelli, L., Venditti, M., Ceccarelli, G., and Oliva, A. (2021). Place in Therapy of the Newly Available Armamentarium for Multi-Drug-Resistant Gram-Negative Pathogens: Proposal of a Prescription Algorithm. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121475"},{"key":"ref_7","unstructured":"(2022, September 08). Overview of Carbapenemase-Producing Gram-Negative Bacilli\u2014UpToDate. Available online: https:\/\/www.uptodate.com\/contents\/overview-of-carbapenemase-producing-gram-negative-bacilli."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106611","DOI":"10.1016\/j.ijantimicag.2022.106611","article-title":"Diagnosis and management of infections caused by multidrug-resistant bacteria: Guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)","volume":"60","author":"Tiseo","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase\u2013Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol-Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: A multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmi.2022.11.005","article-title":"Real world clinical outcome of cefiderocol for treatment of multidrug resistant non-fermenting Gram-negative bacilli infections: A case series","volume":"29","author":"Hoellinger","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e01697-22","DOI":"10.1128\/spectrum.01697-22","article-title":"Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital","volume":"10","author":"Weber","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jiph.2022.07.006","article-title":"Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?","volume":"15","author":"Corcione","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bavaro, D.F., Belati, A., Diella, L., Stufano, M., Romanelli, F., Scalone, L., Stolfa, S., Ronga, L., Maurmo, L., and Dell\u2019Aera, M. (2021). Cefiderocol-Based Combination Therapy for \u201cDifficult-to-Treat\u201d Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060652"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"K\u00f6nig, C., Both, A., Rohde, H., Kluge, S., Frey, O., R\u00f6hr, A., and Wichmann, D. (2021). Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060649"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s15010-022-01933-5","article-title":"Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections","volume":"51","author":"Gavaghan","year":"2022","journal-title":"Infection"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic. Dis."},{"key":"ref_22","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2023, March 01). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 12.0. Available online: http:\/\/www.eucast.org."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1473-3099(13)70081-1","article-title":"Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from randomised prevention studies","volume":"13","author":"Melsen","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"American Thoracic Society, and Infectious Diseases Society of America (2005). Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med., 171, 388\u2013416.","DOI":"10.1164\/rccm.200405-644ST"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT)","volume":"50","author":"Torres","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1055\/s-0041-1740605","article-title":"New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia","volume":"43","author":"Bassetti","year":"2022","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkab280","article-title":"Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia","volume":"76","author":"Katsube","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/jac\/dkac248","article-title":"Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis","volume":"77","author":"Kufel","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.gastro.2019.07.064","article-title":"American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis","volume":"158","author":"Baron","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10096-022-04503-7","article-title":"In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii","volume":"41","author":"Ni","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"AAC0264620","DOI":"10.1128\/AAC.02646-20","article-title":"In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii","volume":"65","author":"Nguyen","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00559-20","DOI":"10.1128\/AAC.00559-20","article-title":"Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","unstructured":"(2023, March 01). Eucast: Cefiderocol Susceptibility Testing. Available online: https:\/\/www.eucast.org\/eucast_news\/news_singleview\/?tx_ttnews%5Btt_news%5D=493&cHash=22779384b74c8cf2c55aa3f7fd69d173."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1172.e7","DOI":"10.1016\/j.cmi.2021.04.016","article-title":"Cross-resistance to cefiderocol and ceftazidime\u2013avibactam in KPC \u03b2-lactamase mutants and the inoculum effect","volume":"27","author":"Hobson","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e02347-22","DOI":"10.1128\/spectrum.02347-22","article-title":"Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability","volume":"10","author":"Stracquadanio","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Marino, A., Stracquadanio, S., Campanella, E., Munaf\u00f2, A., Gussio, M., Ceccarelli, M., Bernardini, R., Nunnari, G., and Cacopardo, B. (2022). Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations. Antibiotics, 12.","DOI":"10.3390\/antibiotics12010049"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"i21","DOI":"10.1093\/jacamr\/dlab055","article-title":"Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection","volume":"3","author":"Mabayoje","year":"2021","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Falcone, M., Tiseo, G., Carbonara, S., Marino, A., Di Caprio, G., Carretta, A., Mularoni, A., Mariani, M.F., Maraolo, A.E., and Scotto, R. (2023). Mortality attributable to bloodstream infections caused by different carbapenem-resistant Gram negative bacilli: Results from a nationwide study in Italy (ALARICO Network). Clin. Infect. Dis., ciad100.","DOI":"10.1093\/cid\/ciad100"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/4\/746\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:15:23Z","timestamp":1760123723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/4\/746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["antibiotics12040746"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12040746","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]}}}